Interferons clinical applications

Interferons represent an important family of biopharmaceutical products. They have a proven track record in the treatment of selected medical conditions, and their range of clinical applications continues to grow. It is also likely that many may be used to greater efficacy in the future by their application in combination with additional cytokines. 

Estrov, Z. 1993. Interferons, Basic Principles and Clinical Applications. R.G. Landes. Fitzgerald, K. 2001. The Cytokine Facts Book. Academic Press. 

Stuart-Harris, R. 2005. Clinical Applications of the Interferons. Hodder Arnold, NC, USA. 

Jonasch, E. and Haluska, F. 2001. Interferon in oncological practice review of interferon biology, clinical applications and toxicities. Oncologist 6(1), 34-55. 

The possibility that interferons can be used as pharmacologic agents has aroused a great deal of interest. Recombinant DNA techniques and cell tissue cultures have been used to produce sufficient quantities of interferons for clinical drug trials. The rationale is that exogenously administered interferons will produce antiviral and other beneficial effects in healthy cells in a manner similar to their endogenously produced counterparts. Some of the pertinent aspects of interferon action and clinical applications are presented below. 

Baron S,Tyring SK, Fleischmann WR Jr,Coppenhaver DFI, Niesel DW, Klimpel GR, Stanton GJ, FlughesTK.The interferons. Mechanisms of action and clinical applications. JAMA 1991 266 1375-1383. 

Jonasch E and Haluska EG. Interferon in Oncological Practice Review of Interferon Biology, Clinical Applications, andToxicities. Oncologist 6 34-55, 2001. 

Lindsay K, et al. Quantitative detection of hepatitis C vims RNA with a solid-phase signal amplification method Definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994 19 1337-41. 

Folkman J, Mulliken JB, Ezekowitz RAB (1997) Antiangio-genic therapy of hemangiomas with interferon-alpha. In Stuart-Harris R, Penny RD (eds) Clinical applications of the interferons. Chapman Hall Medical, London, pp 255-265... 

Intr duc lop - This year, as in the past, reviews of antiviral chemotherapy have appeared in many forms, especially for those interested in clinical applicability. " More extensive discussions of selected areas of interest and a broad overview of the types of viral agents involving the respiratory tract have also appeared. Emphasis will be given to the current status of ascorbic acid as a clinically available therapeutic substance in relation to viral diseases. The clinical status of rlfamy-cin SV derivatives, pyrimidine nucleosides, and interferon will also be commented upon. An exciting new class of biS-basic-substituted polycyclic aromatic compounds was the subject of additional evaluation during the past year.6... 

Gaboli M, Gandini Delva L, Wang ZG, Pandolfi PP (1998) Acute promyelocytic leukemia as a model for cross-talk between interferon and retinoic acid pathways from molecular biology to clinical applications. Leuk Lymphoma 30 11-22... 

Some cytokines have already gained approval for medical use. Many more are currently undergoing clinical or preclinical trials. Over the next few chapters the biology and potential medical applications of these cytokines will be discussed in detail. The remainder of this chapter concerns itself with the prototypic cytokine family, namely the interferons. 

The anti-viral and anti-proliferative activity of IFNs, as well as their ability to modulate the immune and inflammatory response, renders obvious their potential medical application. This has culminated in the approval for clinical use of several interferon preparations (Table 4.8). 

Platanias, L.C., and H.M. Golomb, Clinical use of interferon Hairy cell, chronic myelegenous and other leukemias, in Interferon principles and medical applications. 1992, Galveston University of Texas, Galveston Medical Branch. 427-32. 

Rhizopus oryzae lactate dehydrogenase 24 rhizosecretion 48 ribosome 13 rice 27 rifamycin 14 rituxan 213 rituximab 213 application 226 approval 225 B-cell recovery 222 clinical development 215 combination 223 development 221 EMEA 225 first phase I study 219 future applications 226, 228 IDEC 219 indications 226 interferon 224 mechanism of action 215 optimizing the dose and schedule 222 pharmacokinetic 222 phase I and I/II clinical trials 219 phase I/II 216... 

---